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Abstract
Background: Despite the fact that approximately 70% of Canadian women undergo cervical cancer screening at least
once every 3 years, approximately 1,300 women were diagnosed with cervical cancer and approximately 380 died from
it in 2008. This study estimates the effectiveness and cost-effectiveness of vaccinating 12-year old Canadian females with
an AS04-adjuvanted cervical cancer vaccine. The indirect effect of vaccination, via herd immunity, is also estimated.
Methods: A 12-health-state 1-year-cycle Markov model was developed to estimate lifetime HPV related events for a
cohort of 12-year old females. Annual transition probabilities between health-states were derived from published
literature and Canadian population statistics. The model was calibrated using Canadian cancer statistics. From a
healthcare perspective, the cost-effectiveness of introducing a vaccine with efficacy against HPV-16/18 and evidence of
cross-protection against other oncogenic HPV types was evaluated in a population undergoing current screening
practices. The base-case analysis included 70% screening coverage, 75% vaccination coverage, $135/dose for vaccine, and
3% discount rate on future costs and health effects. Conservative herd immunity effects were taken into account by
estimated HPV incidence using a mathematical model parameterized by reported age-stratified sexual mixing data.
Sensitivity analyses were performed to address parameter uncertainties.
Results: Vaccinating 12-year old females (n = 100,000) was estimated to prevent between 390-633 undiscounted
cervical cancer cases (reduction of 47%-77%) and 168-275 undiscounted deaths (48%-78%) over their lifetime, depending
on whether or not herd immunity and cross-protection against other oncogenic HPV types were included. Vaccination
was estimated to cost $18,672-$31,687 per QALY-gained, the lower range representing inclusion of cross-protective
efficacy and herd immunity. The cost per QALY-gained was most sensitive to duration of vaccine protection, discount
rate, and the correlation between probability of screening and probability of vaccination.
Conclusion: In the context of current screening patterns, vaccination of 12-year old Canadian females with an ASO4-
ajuvanted cervical cancer vaccine is estimated to significantly reduce cervical cancer and mortality, and is a cost-effective
option. However, the economic attractiveness of vaccination is impacted by the vaccine's duration of protection and the
discount rate used in the analysis.
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Background
Despite a large decline (>60%) in cervical cancer inci-
dence and mortality since the implementation of screen-
ing in Canada in the 1960s, an estimated 1,300 women
were diagnosed with cervical cancer and approximately
380 died in 2008 [1]. The guidelines for screening for can-
cer of the cervix in Canada state that all women aged 18
and over be screened, initially with two smears one year
apart. If these smears are satisfactory then rescreening
every three years is advised until the age of 69 [2]. The best
national data currently available show 1 year participation
rates do not vary greatly among provinces, ranging from
37% in British Columbia and Ontario to 44% in Nova
Scotia. The 3-year participation rate in Canada is approxi-
mately 70% [3]. Despite screening programs, cervical can-
cer mortality has declined only marginally since 1990 [4].
Strong evidence points to specific high-risk human papil-
lomavirus (HPV) types as the causative agent of the vast
majority of cancerous and precancerous cervical lesions
[5]. Specifically, HPV 16 and HPV 18 are implicated in
approximately 70% of cervical cancers [3], and other
high-risk HPV types including 31, 45, 33, 52 have been
found to contribute an additional 14.5% [6]. Canadian
data show that 85% of all HPV infection costs are related
to screening and follow-up procedures, amounting to
$250-$300 million annually [7].
In February 2007, the National Advisory Committee on
Immunization (NACI) recommended vaccination of
women between 9 and 13 years of age[4]. According to the
Canadian Immunization Committee(CIC)-NACI HPV
Working Group, the goal of an HPV immunization pro-
gram in Canada is to decrease the morbidity and mortality
of cervical cancer, its precursors and other HPV-related
cancers in women through a combination of primary and
secondary prevention strategies [4]. Two HPV vaccines
exist at present, a quadrivalent HPV 6/11/16/18
(Gardasil®, Merck Frosst) currently available in Canada,
and an HPV 16/18  AS04-adjuvanted vaccine (Cervarix™,
GlaxoSmithKline) under regulatory review by Health
Canada. Both vaccines are highly efficacious and safe [8-
13]. Immunity against HPV is thought to be primarily
type-specific [14-18], however there is some cross-protec-
tion between genetically related types. The HPV-16/18
AS04-adjuvanted vaccine is reported to provide high effi-
cacy against CIN2+ associated with HPV-16/18 as well as
non-vaccine oncogenic HPV individual types including
HPV 45, HPV 31, HPV 33 [8,9]. Broad protection against
CIN2+ infection with combined oncogenic, non-vaccine
HPV types, suggesting that cross-protection might extend
beyond types 45 and 31 [8,9]. In addition, substantial
overall effect is reported in cohorts that are relevant to
universal mass vaccination and catch-up programmes[8].
By reducing the amount of HPV transmission in the pop-
ulation, vaccination also reduces the risk of infection to
unvaccinated individuals. This effect is termed herd
immunity or herd protection[19,20], and its inclusion in
the assessment of HPV vaccination generally results in
lower cost-effectiveness ratios under certain common con-
ditions [21-25]. Accounting for herd protection effects in
a cost-utility analysis normally requires use of a dynamic
model and thus abandonment of the spreadsheet-based
cohort modeling framework often used for vaccination
cost-effectiveness analysis[26].
Several studies have examined the cost-effectiveness of
HPV vaccination in different countries. Though studies
vary in model type, input data, and model assumptions,
most of them have shown that HPV vaccination is likely
to be cost-effective in pre-adolescent females[7,22-25,27-
30,30,31,31-36]; however, the inclusion of male vaccina-
tion was generally not cost-effective[22-25,35] or in some
cases less cost-effective and including catch-up programs
was also less cost-effective[23,25]. Sensitivity analyses
demonstrated that cost-effectiveness estimates of HPV
vaccine are largely influenced by factors such as the dis-
count rate, vaccine cost, vaccine efficacy, coverage, and
duration of vaccine protection[7,22,25,27-31,33,34,36].
In this study, we estimate the effectiveness and cost-effec-
tiveness of an AS04-adjuvanted cervical cancer vaccine in
a hypothetical cohort of 12-year old females, in the con-
text of current cervical cancer screening programs. We use
a recently-developed methodology based on equations
derived from dynamic models to conservatively account
for herd immunity effects in the context of an existing
spreadsheet-based Markov cohort model for HPV vaccina-
tion in Canadian women.
Methods
Model structure
A simple and transparent Markov model was developed in
Microsoft Excel that allows for rapid and flexible use with
a primary focus on cervical cancer. This model was vali-
dated against a more complex model and adapted for its
application to the Canadian setting[37,38]. Figure 1 dis-
plays the model schematics.
The Markov model replicates the natural history of cervi-
cal disease over the lifetime of the cohort in one-year
cycles and in the following health states: Normal, HPV
infection (high-risk, low-risk), Cervical Intraepithelial
Neoplasia (CIN), Cervical Cancer, Cervical Cancer Death,
and Other Death. Transition probabilities were age and
HPV-type (high-risk, low-risk) specific and derived
through the literature. Women in the model can progress
and regress from states up to persistent CIN2,3 and there-
after may progress to cervical cancer. Women in the cancer
state can either remain in cancer or move to a 'cured' can-
cer state and remain there over their lifetime. A simplified
screening module is incorporated, with no follow-up test-BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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ing after a negative cytology result, and colposcopy and
biopsy with treatment after a positive cytology result. Reg-
ular (i.e., 70% women are screened every 3 years), irregu-
lar (i.e., 18% various screening patterns), and never
screened (i.e. 12%) are taken into account[39]. Sensitivity
for screening is incorporated to estimate the proportion of
patients with their disease detected and treated. Natural
immunity after HPV infection was not accounted for in
the model. The number of sexual partners, age at first
pregnancy, race and socioeconomic status are surrogate
markers for infection with HPV[40] but were not included
in the model.
Calibration
The model was calibrated by manually manipulating
input parameters to match the model output to observed
epidemiological data while keeping transition probabili-
ties within pre-determined ranges of plausibility. Age-spe-
cific cervical cancer incidence and mortality rates[41], as
well as the overall number of cases and deaths estimated
by the model were matched to observed data during this
process. To validate the matching between the observed
epidemiological data and model-predicted data, we con-
ducted a chi-square test for significance at the level of p <
0.05.
Vaccine efficacy
Vaccine efficacy is modelled by assuming it causes a reduc-
tion in the probability of acquiring HPV infection. The
model uses an overall average vaccine effectiveness
against all oncogenic types, computed as the average effi-
cacy against HPV 16/18, and other non-vaccine oncogenic
HPV types weighted by prevalence of cervical cancer
attributed to each HPV-type[6]. Based on recently pub-
Cohort model structure Figure 1
Cohort model structure. 12-disease state Markov process model with 12 month cycle, simulates natural history of HPV 
infection and cervical cancer. Transition rates vary by age, HPV type, screening, treatment, vaccination. Simple screening mod-
ule. Detected: subjects with disease detected through screening have same pathways but different probabilities. CIN: Cervical 
Intraepithelial Neoplasia.
No oncogenic HPV infection 
Other death 
Death from cancer 
CIN1 oncogenic 
CIN 2/3 
Cured cancer 
Oncogenic HPV 
Cervical Cancer 
Vaccine 
detected 
detected 
detected  Persistent CIN 2/3 BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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lished data, we used 98% efficacy against HPV 16 and 18
infections and 37% for other non-vaccine oncogenic
types[8,9]. Long-term data on vaccine efficacy is not cur-
rently available. Recently data shows strong and sustained
antibody response for HPV 16 and HPV 18 up to 7.3 years
post-vaccination [10,42] and mathematical models have
predicted the long term vaccine duration to be at least 20
years[43]. Lifelong vaccine protection was assumed for
the base-case analysis, and shorter duration times were
tested in the sensitivity analysis. To prevent over-estima-
tion of the vaccine benefit on the incidence of CIN events,
CIN1 and CIN2,3 were thereafter added to take into
account the difference between the proportion of HPV in
CIN and cancer.
Herd immunity
Herd protection effects were included within the cohort
model through a pseudo-dynamic approximation based
on the adaptation of a standard compartmental dynamic
model, the Susceptible-Infectious-Recovered (SIR)
model[44]. The model was calibrated using published
estimates of HPV transmissibility[45,46]. The model
equations were solved to determine the risk of infection to
unvaccinated individuals in a population with a given
level of vaccine coverage. This was combined with age-
stratified data on sexual mixing patterns to determine the
age-specific change in infection risk over time for those
members of an aging cohort of women not successfully
vaccinated under the vaccination program[24,47]. This
change in infection risk was represented by a multiplica-
tive factor rherd, representing the proportionate reduction
in infection risk due to herd immunity effects. For
instance,  rherd = 0.5 means that susceptible individuals
have their infection risk reduced by 50% due to vaccina-
tion in other members of the population). rherd can be set
to 1 when herd immunity is not taken into account
through this pseudo-dynamic approximation, i.e., when
infection risk is assumed constant as under conventional
Markov cohort models of vaccination. Details of the
methodology appear in [47].
Costs and Quality Adjusted Life Years (QALYs)
Total costs, total QALYs, number of cervical cancer cases,
and number cervical cancer deaths were derived over the
lifetime of one birth cohort of girls after assigning specific
costs and QALY to each health state and cumulating those
over the lifetime. Utilities for pre-cancer and cervical can-
cer were taken from the literature. The disutility of pre-
cancer and cancer health states were subtracted from age-
specific utility in the general population.
Data on costs were obtained from Canadian literature,
though some of the data cited in the publications were
derived from the US [7,48]. When necessary, costs were
inflated to 2006 using the health and personal care com-
ponent of the Consumer Price Index[49]. The cost of the
vaccine was assumed to be $135 per dose. Cost of vaccine
administration was not included in the base case analysis,
though this may be represented in the upper bound of the
vaccine cost in the sensitivity analysis. Cost for adverse
events was not included, though HPV vaccine has been
shown to have an excellent safety profile. Future costs and
health effects were discounted at 3% and varied in sensi-
tivity analyses.
Table 1 provides a summary of the input parameters and
data sources. Base case estimates and ranges were deter-
mined using a combination of literature or best assump-
tion. Data was Canadian-specific whenever possible.
Base case
Vaccination is evaluated in a hypothetical cohort of
100,000 12-year old Canadian girls. This age was chosen
as the target group for vaccination because it represents
women prior being at risk for HPV infection (i.e. before
sexual debut). HPV vaccination rates differ across Canada
by province. According to a Canadian report, HPV vacci-
nation rates among school-based cohorts was 80% in
Atlantic provinces, 85% in Newfoundland, 85-87% in
Quebec, and 53% in Ontario [50]. Based on this variabil-
ity we assumed a base-case rate of 75%. It was assumed
that all adolescents would receive three doses of the vac-
cine and be fully immunized after 1 year. Vaccination is
compared with the Canadian status quo for cervical can-
cer prevention, cytological (Pap) screening. For this anal-
ysis, we assume that current screening patterns will not
change with implementation of vaccination. Four scenar-
ios are included in base case analyses based on the inclu-
sion or exclusion of herd protection and cross-protective
efficacy. Sensitivity analysis was conducted on all four sce-
narios.
We conducted a cost-utility analysis from the perspective
of the healthcare system (i.e., only direct costs to the
healthcare system were taken into account), evaluating
the incremental cost per QALY gained.
The incremental cost-utility ratio is calculated as:
where program A is current cervical cancer screening, and
program B is cervical cancer vaccination plus current
screening. As a threshold to decide whether the estimated
incremental cost-effectiveness ratio (ICER) could be
deemed cost-effective, we use the gross domestic product
(GDP) per capita for Canada, $37,000 (2006 est.)[51].
costs accrued under B - costs accrued under A
QALYs accrued   under B - QALYs accrued under A
(1)BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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Table 1: Summary of input parameters into health economic model
Input parameters Base Case Value References
Vaccination
Efficacy HPV 16/18 98% (95% CI: 88.4-1000) [8-11]
Efficacy non-vaccine oncogenic HPV types 37% (95% CI: 7.4-58.0) [8,9]
Duration of vaccine protection lifelong Assumption
Coverage rate 75% Assumption based on [50]
Screening
Age and frequency Age 18-69, 70% (once/3 years), 12% (never) [39]
Cytology (Pap) test sensitivity 55.4% [57]
Cytology (Pap) test specificity 96.8% [57]
Costs and utilities
Vaccination costs
Vaccine per dose $135.00 Assumption
Screening Costs
Conventional cytology $57 [7,48]
Colposcopy + Biopsy $150 [7,48]
Treatment Costs (annual)
CIN 1 $782 [7,48]
CIN 2/3 $1,353 [7,48]
Cervical cancer stage 1 $11,915 [7,48]
Cervical cancer stage 2 $18,851 [7,48]
Cervical cancer stage 3 $18,851 [7,48]
Cervical cancer stage 4 $25,759 [7,48]
Utilities
Normal Population 0.94-0.89 (age-specific) [58]
CIN lesion 0.96-0.995 [59,60]
Cervical cancer 0.73 [59,60]
Cured cancer 0.94 [61]BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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Sensitivity analysis
To deal with uncertainty in parameter values, sensitivity
analyses were conducted to determine the impact of vary-
ing parameter values on the cost per QALY-gained. Several
input parameters were varied within a pre-specified range
of values based on published literature or best/worst case
assumptions These included vaccine parameters (efficacy,
duration of protection, coverage rate, age at vaccination),
screening parameters (frequency), economic parameters
(vaccine cost, screening costs, disease costs, discount rate),
and quality of life parameters (utilities). We also tested a
non-zero correlation between probability of screening
and probability of vaccination, based on a Canadian sur-
vey of 500 adult women that found that contrary to their
initial hypothesis, a higher proportion of females who
had less regular screening tests were willing to recom-
mend an HPV vaccine to their daughters/nieces [52]. For
vaccine waning scenarios, we assume that vaccine efficacy
does not wane until a specific time period after initial vac-
cination (e.g. 10 years, 30 years) after which it begins to
wane linearly over a period of 5 years. Upper bound
screening were varied by 50% from base case, as a recent
review suggests the base case costs we used are conserva-
tive [48].
Results
Calibration
The model predicted and observed rates of cervical cancer
incidence and deaths are compared in Figure 2. The mod-
eled number of cumulative cervical cases over the lifetime
of a 12 year old cohort is well matched to observed Cana-
dian data (822 and 824, respectively). The model reflects,
with a slight overestimation, the average Canadian cervi-
cal cancer death rates with a predicted cumulative 350
deaths compared with 319 observed over the lifetime of
the cohort. The total number of observed vs. modeled cer-
vical cancer cases and deaths were tested for differences
using a Chi-square test for significance and evaluated at
the p = 0.05 level. No statistically significant differences
were found. Predictions are well matched to Canadian
estimates when looking across five-year age groups as
shown in figure 2.
In addition, the model predicts a cumulative 105,960
cases of CIN1 and 26,100 CIN2,3 compared with the
105,922 CIN1 and 25,294 CIN2,3 expected using the
same epidemiologic data [41].
Effectiveness of Vaccination
With a 75% vaccination rate, undiscounted base case sce-
nario results estimate 390-457 cervical cancer cases and
168-196 cervical-related deaths would be prevented over
the life-time a cohort of 100,000 girls vaccinated at 12
years of age compared with an unvaccinated cohort (Table
2). Discounted cases prevented ranged from 118-138 and
38-44 for cervical cancer and deaths, respectively. This
represents at least a 47% reduction in cases and deaths.
Taking into account herd protection effects, the estimated
reduction in cervical cancer cases and deaths increases up
to 77%-78%
Under a scenario where protection from the vaccine
wanes after 10 years, the estimated reduction in undis-
counted lifetime cancer cases and deaths is at least 9% and
4%, respectively (Table 2). With a vaccine with 30 years
duration of protection the estimated reduction in undis-
counted lifetime cancer cases and deaths is at least 22%
and 13%, respectively. When herd protection effects are
included, the estimated reductions in cervical cancer cases
and deaths increase quite significantly to at least of 21%
and 34% for 10 and 30 year duration of vaccine protec-
tion, respectively.
Cost-utility of vaccination
Table 3 shows predicted cost-utility results in a vaccinated
cohort under the base case scenarios compared with an
unvaccinated cohort undergoing the same screening and
treatment scenario. Compared with no vaccination, vacci-
nating 100,000 girls aged 12 years resulted in incremental
QALYs gained of 0.0083-0.0095 per person and an incre-
mental cost of $256 - $263 over the lifetime of the cohort.
The resulting discounted cost per QALY gained for vacci-
nation was in the range of $26,947 - $31,687 depending
on whether or not cross-protection was included. The
inclusion of herd immunity reduced the cost per QALY
gained by 12% - 31%.
Sensitivity Analysis
Figure 3 shows results of the sensitivity analysis for vacci-
nation with HPV 16/18 with cross-protective efficacy,
with and without herd immunity. Results for HPV 16/18
only were similar, and therefore not shown here. HPV vac-
cination remained cost-effective for the most part (the
cost per QALY gained remained below $37,000). The cost
per QALY gained was less sensitive to changes in parame-
ter values when herd immunity was included in the
model.
The cost per QALY gained was generally not sensitive to
changes in disease and screening costs, coverage, and age
of vaccinated cohort. The cost per QALY gained was some-
what sensitive to changes in vaccine efficacy, and vaccine
cost, though values still remained under the cost-effective-
ness threshold.
Overall, the parameters that had the most impact on the
cost per QALY-gained included the discount rate, duration
of vaccine protection, and the correlation between proba-
bility of screening and probability of vaccination. Varying
the discounting rates from 0% to 5% showed the greatestBMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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Model Calibration: Observed vs. model predicted cases and deaths Figure 2
Model Calibration: Observed vs. model predicted cases and deaths. Note: The total number of observed vs. modeled 
cervical cancer cases and deaths were tested for differences using a Chisquare test for significance and evaluated at the p = 
0.05 level. No statistically significant differences were found.
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impact on the cost-utility ratio. The cost per QALY-gained
varied from a low of $2,000 - $4,000 when a 0% discount
rate was applied, to $50,000 - $69,000 when the discount
rate was set to 5%. Given the lack of data on long-term
duration of vaccine protection, we tested various waning
immunity and booster scenarios. A scenario of linear wan-
ing of vaccine-derived immunity starting after 10 years of
constant protection was the least effective strategy and
resulted in cost per QALY-gained $68,000 and $100,000
with and without a booster, respectively. When herd pro-
tection effects are included, the cost per QALY-gained
remains under the cost-effectiveness threshold. Results
show that when protection is assumed to last 30 years, the
cost per QALY does not change significantly when a
booster is added, particularly when herd protection effects
are included.
Our results indicate that if screening frequency and vacci-
nation rates have a positive correlation (i.e. women who
are infrequently or never screened are less likely to get vac-
Table 2: Undiscounted lifetime risk-reduction in burden of disease for bases case analyses, by duration of vaccine protection
No herd immunity With herd immunity
HPV 16/18 HPV 16/18 + cross-protection HPV 16/18 HPV 16/18 + cross-protection
Cancer Cases
No. cases no vaccination 822 822 822 822
No. cases with vaccination 432 365 369 189
No. cases prevented 390 457 453 633
% reduction 47.4% 55.6% 55.1% 77.0%
vaccine duration = 30 y 22.3% 26.2% 34.0% 61.6%
vaccine duration = 10 y 9.0% 9.0% 21.1% 51.8%
Cancer Deaths
No. deaths no vaccination 351 351 351 351
No. deaths with vaccination 183 155 150 76
No. deaths prevented 168 196 201 275
% reduction 47.9% 55.8% 57.3% 78.3%
vaccine duration = 30 y 12.8% 15.1% 29.1% 57.7%
vaccine duration = 10 y 4.0% 4.0% 20.8% 51.4%
75% vaccination coverage.
Vaccine duration of protection: assumes initial vaccination efficacy lasts to 10 years, then wanes linearly over a 5 year period until 0% efficacy at year 
16. 30 year scenario: efficacy lasts to 30 years, then wanes linearly for 5 year period until 0% efficacy at year 36.
Table 3: Discounted cost, QALYs, and cost per QALY results for base case analyses, 3% discount, 75% vaccination coverage.
Average cost and QALYs per person Non-Vaccinated cohort Vaccinated cohort Incremental Cost per QALY
No Herd Immunity
HPV 16/18
Total Cost $476 $739 $263
Total QALYs 30.5015 30.5098 0.0083 $31,687
HPV 16/18 + cross protection
Total Cost $476 $732 $256
Total QALYs 30.5015 30.5110 0.0095 $26,947
With Herd Immunity
HPV 16/18
Total Cost $476 $735 $259
Total QALYs 30.5015 30.5108 0.0093 $27,849
HPV 16/18 + cross protection
Total Cost $476 $715 $239
Total QALYs 30.5015 30.5143 0.0128 $18,672BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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Sensitivity analysis results for vaccination with HPV 16/18 + cross-protection, with and without herd immunity Figure 3
Sensitivity analysis results for vaccination with HPV 16/18 + cross-protection, with and without herd immunity.BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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cinated and vice versa), the cost per QALY-gained
increases to $42,000. When herd immunity is taking into
account, the cost per QALY-gained remains under the
cost-effective threshold. If a negative correlation is
assumed (i.e. women who are infrequently or never
screened are more likely to get vaccinated and vice versa),
the cost per QALY-gained decreases from our base case
analysis, but does not go under $15,000 with or without
inclusion of herd immunity.
Though no single parameter tested has resulted in a cost-
savings situation, a multivariate sensitivity analysis that
included varying only those parameters that had a posi-
tive impact on the cost per QALY-gained (i.e. lifelong vac-
cine protection, 0% discounting, lower vaccine cost),
resulted in a very low cost per QALY gained of $1,000 -
$2,000. Varying only the parameters that had a negative
impact on the cost per QALY-gained (i.e. 10 year vaccine
protection, 5% discounting, low vaccination rates among
under-screened or never screened women) resulted in a
cost per QALY-gained of $84,000 when herd protection
was included to >$100,000 when herd immunity was not
included.
Discussion
The results from this cost-utility study suggest that within
the context of current cervical cancer screening programs
in Canada, cervical cancer vaccination of pre-adolescent/
adolescent females is likely to be cost-effective from a
healthcare perspective. These results were robust at the
threshold of $37,000 per QALY-gained and under a wide
range of assumptions and parameter uncertainties.
Including herd immunity effects was estimated to increase
base case vaccine effectiveness by approximately 8% -
23% and cost-effectiveness by 12% - 31%. Increases in
vaccine effectiveness and cost-effectiveness are consistent
with other economic analyses of HPV vaccination that
have accounted for herd immunity effects [22-25,29]. Our
base case cost-utility ratios are consistent with other Cana-
dian analyses evaluating quadrivalent HPV female vacci-
nation in a cohort model [7] and HPV 16/18 female
vaccination in a dynamic model [53], showing cost per
QALY-gained ranging from $21,000 - $33,115 per QALY-
gained.
Our results indicate increased effectiveness and cost-effec-
tiveness with a bivalent HPV 16/18 vaccine that confers
cross-protection against other non-vaccine oncogenic
HPV types (e.g. HPV 31, 33, 45) [8,9], though longer term
clinical trial data is needed to understand vaccine efficacy
for these individual HPV types. The inclusion of cross-pro-
tective efficacy led to greater disease and mortality reduc-
tions. Cross-protective efficacy alone without accounting
for herd immunity resulted in an additional 67 cancer
cases prevented and 28 deaths prevented.
Consistent with other cost-effectiveness studies of HPV
vaccination [7,25,29,33,34,53], our results were sensitive
to the discount rate and duration of vaccine protection.
Because of the long latency between HPV vaccination and
cervical cancer averted due to vaccination, we found that
varying the discounting rates showed the greatest impact
on the cost-utility ratio. According to much of the health
economic literature, health effects should be discounted
at the same rate as costs, however; some argue that health
effects should be discounted at a lower rate than costs
[54]. Others have suggested that discounting for vaccines
should start from the time of risk reduction rather than
the time of intervention [55,56].
Our results also suggested that duration of vaccine protec-
tion is important in the effectiveness and cost-effective-
ness of vaccination. A vaccine where protection starts to
wane before 30 years would result in less than a 26%
reduction in cumulative cancer cases and 15% in deaths.
A booster shot for older females may be warranted in this
case, however vaccination compliance is often lower for
adult programs than for school-based programs. For
instance, compliance for adult Hepatitis A vaccination
programs in Canada has been estimated to be 25% [26].
Under herd immunity, our results suggest that individuals
who lose their vaccine-derived immunity later in life may
still derive some indirect protection through herd immu-
nity effects. However given the uncertainty and sensitivity
of this parameter, surveillance of populations in coming
years to determine the long-term duration of protection
from HPV vaccines will be needed.
The cost-utility ratios are similar for various possible ages
of vaccination between the ages 12-25. However, one
should expect that vaccination at a younger age should
generally result in lower cost-utility ratios, since more
infection is thereby averted. In our results, cost-utility
ratios may be similar across this age range because (a)
HPV prevalence in Canada peaks at age 20-25, therefore
vaccination before age 20 will prevent only a small
number of additional events relative to vaccination at age
12, and (b) future cancer cases averted are discounted
more heavily for vaccination at a younger age, which
reduces estimated QALYs gains from a given expenditure
on vaccination. This is confirmed by analyzing undis-
counted results, in which the most favorable cost-effec-
tiveness ratio is shown in the younger age cohort.
Our results also indicated that cost-effectiveness improves
when women who are under-screened or never screened
have higher vaccination rates than those women who are
more frequent screeners. This occurs because the women
who are vaccinated are those most at-risk for cervical can-
cer (i.e. under-screened or never screened), but fewer
women in the total cohort are being vaccinated and there-BMC Public Health 2009, 9:401 http://www.biomedcentral.com/1471-2458/9/401
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fore the total vaccine costs for cohort are reduced. How-
ever, the most effective strategy in terms of disease
reduction occurs when a high coverage rate is to the entire
cohort, irrespective of screening frequency, and this strat-
egy remains below the cost-effectiveness threshold.
There are several limitations that should be noted. The
model slightly overestimated the average Canadian cervi-
cal cancer death rate. It is possible that this could bias the
study results in favour of the vaccine program. However,
as noted earlier, our results are consistent with other eco-
nomic analyses of cervical cancer vaccination in Canada
and elsewhere. Varying levels of HPV infection in a popu-
lation will have an impact on effectiveness and cost-effec-
tiveness of vaccination programs and it is important to
note that this was not taken into account here. Also, our
base case value of vaccine cost was based on an assump-
tion and did not include vaccine administration costs.
Vaccine administration costs will vary depending on the
vaccination strategy (e.g., new school-based program ver-
sus adding HPV vaccine to a pre-existing school-based
program), therefore, it is important to look at the range of
the cost-utility ratios in the sensitivity analysis under vac-
cination costs. Even in our upper range estimate of vaccine
cost, the cost per QALY-gained was within the range of
what is considered cost-effective.
We used a simple model to estimate the effectiveness and
cost-effectiveness of cervical cancer vaccination in 12-year
old females in Canada. This spreadsheet model requires
fewer data and programming calculations which allows
for rapid and flexible use. The value of such a simple
model is that data requirements are more modest, which
may suit its application to policy development in jurisdic-
tions where data availability and/or quantity are limited.
At the same time, this model has been validated against a
more complex model and predicts similar cost-effective-
ness [37]. We conservatively incorporated herd immunity
effects in this cohort model of cervical cancer vaccination.
The fullest and most accurate way to account for herd
immunity effects is through a dynamic model, however,
the approach described here allows us to approximate
herd immunity on effects in the context of an existing
spreadsheet-based cohort model under certain condi-
tions. This may be useful as a means of preliminary incor-
poration of herd immunity effects preceding development
of a full dynamic model.
This type of model can help inform policy until more
complex models (i.e. sexual network transmission mod-
els) are available to answer and understand more in-depth
policy questions. Some of the policy questions that will
need to be explored are the long-term effectiveness and
cost-effectiveness of current and possible modified cervi-
cal cancer screening policies (e.g. longer screening inter-
vals and new technologies such as liquid-based cytology,
HPV DNA testing) in the context of HPV vaccination in
Canada.
Conclusion
Using a recently-developed methodology to conserva-
tively account for herd immunity effects in the context of
an existing cohort model, our results suggest that immu-
nization of pre-adolescent Canadian females with an
ASO4-adjuvanted cervical cancer vaccine in 12 year old
females is both effective at reducing cervical disease and
deaths and is cost-effective when compared with cervical
screening alone. However, the cost-effectiveness is highly
influenced by the duration of protection of the vaccine
and the discount rate used in the analysis.
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